



DLA Piper US LLP
 153 Townsend Street, Suite 800
 San Francisco, California 94107-1957
www.dlapiper.com

Linda R. Judge
linda.judge@dlapiper.com
 T 415.836.2586

RECEIVED
CENTRAL FAX CENTER

NOV 21 2006

FAX TRANSMISSION COVER SHEET

Date: November 21, 2006

To	<u>Telephone</u>	<u>Fax Number</u>
Attn: Group Art Unit 1644 United States Patent and Trademark Office		571.273.8300
From: Linda R. Judge 415/836.2586		Client-Matter Number: 306229-114
Re: U.S. Application No.: 10/807,449		
Entitled:	CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS	
Filing Date:	March 24, 2004	
Inventor:	Jooss, et al.	
Art Unit:	1644	
Examiner:	Ouspenski, I.I.	
Attorney Docket No.:	3802-090-27 CIP	
Pages: -11- (including this form)	Originals: will not follow	

If there is a problem with this transmission, please call DLA Piper Office Services at 415.836.2500,
ext. 6104

Fax Operator/Ext. _____

Message:

Please find the following papers included in this filing:

1. Transmittal; and
2. Amendment and Response to Restriction Requirement.

Thank you.

CONFIDENTIALITY NOTICE

This communication is ONLY for the person named above. Unless otherwise indicated, it contains information that is confidential, privileged or exempt from disclosure under applicable law. If you are not the person named above, or responsible for delivering it to that person, be aware that disclosure, copying, distribution or use of this communication is strictly PROHIBITED. If you have received it in error, or are uncertain as to its proper handling, please immediately notify us by collect telephone and mail the original to us at the above address. Thank you.

(Form Rev. 8/02/04)

SANF11359483.1

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in this Submission: 10


Application No.	10/807,449	RECEIVED
Filing Date	March 24, 2004	CENTRAL FAX CENTER
First Named Inventor	Jooss, et al.	NOV 21 2006
Group Art Unit	1644	
Examiner Name	Ouspenski, I.I.	
Attorney Docket No. 3802-090-27 CIP (306229-114)		

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After-Allowance Communication to TC
<input type="checkbox"/> Fee attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> Response to Restriction	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavit/Declaration(s)	<input type="checkbox"/> Combined Revocation and Power of Attorney and 37 C.F.R. §3.73(b) and 3.71 Statements and Request for Change of Attorney Docket Number	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement (IDS)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Substitute PTO Form 1449	<input type="checkbox"/> CD. Number of CD(s) _____	
<input type="checkbox"/> Cited References	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts Notice/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks:
Please address all correspondence to Customer Number 29585
The Director is hereby authorized to charge any fees that may be required in connection with the papers submitted herewith that have been inadvertently omitted, specifically including any extension fees that may be required under 37 CFR § 1.136(a), to Deposit Account No. 07-1896 (Charge No.: 3802-090-27 CIP (306229-114))


SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Signature:		Date	November 21, 2006
Name	Linda R. Judge	Reg. No.	42,702
Address	153 Townsend Street, 8th Floor, San Francisco, CA 94107		

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being filed with the United States Patent and Trademark Office by facsimile transmission on the date indicated below to Facsimile No. 571/273.8300.

Date: November 21, 2006


Print Name

SANFI1359482.1

RECEIVED
CENTRAL FAX CENTER

NOV 21 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jooss, et al.	Docket No:	3802-090-27 CIP (306229-114)
Serial No.:	10/807,449	Confirmation No.:	3354
Filed:	March 24, 2004	Group Art Unit:	1644
For:	CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS	Examiner:	Oupenski, I.I.

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

VIA FACSIMILE to 571/273.8300
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction/Election of Species Requirement in the above-captioned application, dated October 24, 2006, Applicants elect, Groups I – XX (Claims 1-10, 12, 14, 15, 19, 20 and 23-27), and in particular an anti-OX40 antibody, with traverse, for further prosecution at this time.

Amendments of the Claims begin at page 2 of this paper.

Remarks begin on page 8 of this paper.